Xeris Biopharma Holdings, Inc. - Common Stock (XERS)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on January 2, 2026, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 181,550 shares of its common stock to 50 new employee(s) under Xeris’ Inducement Equity Plan.

One of the company's key drugs won't be challenged by a competing medication anytime soon.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its subsidiary Xeris Pharmaceuticals Inc.’s U.S. patent application covering XP-8121, one of its novel product candidates. The Notice of Allowance indicates that the USPTO has determined the application meets the requirements for patentability and is expected to issue as a U.S. patent following standard administrative steps. The allowed claims in this application are specific to the XP-8121 formulation. In parallel, Xeris continues to pursue additional layers of U.S. and international IP protection in the levothyroxine (LT4) technology space.

Xeris Biopharma (XERS) Q3 2025 Earnings Transcript

Xeris Biopharma posts record Q3 2025 revenue of $74.4M, up 37% YoY, but misses earnings estimates. The company raises full-year guidance.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Thursday, November 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2025, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 382,975 shares of its common stock to 40 new employee(s) under Xeris’ Inducement Equity Plan.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced the U.S Patent and Trademark Office has issued patent number 12,377,096 to the Company for Recorlev® (levoketoconazole) and that this patent is now listed in the publication, “Approved Drug Products with Therapeutics Equivalence Evaluations,” commonly known as the “Orange Book.” This patent, entitled “Methods of Treating Disease with Levoketoconazole,” covers therapeutic uses of levoketoconazole in methods that minimize drug-drug interactions between levoketoconazole and other commonly co-administered drugs known as MATE1 substrates, and extends to March 2040.

Let's have a look at the gap up and gap down stocks in today's session.

Xeris Biopharma (XERS) Q2 2025 results beat estimates with $71.5M revenue (+48.8% YoY) and narrower losses. Stock surged 12.2% pre-market as Recorlev sales soared 136%. Raised full-year guidance to $280–$290M.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter ended June 30, 2025, and updated its fiscal 2025 guidance.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Thursday, August 7, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results.

XERIS Biopharma (XERS) meets Minervini’s Trend Template with strong technicals and high growth momentum, including 47.9% quarterly revenue growth and a 93.95 Relative Strength score.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for its first in-person and virtual analyst and investor day in New York City on Tuesday, June 3, 2025, at 10:00 a.m. EST.

XERIS BIOPHARMA (XERS) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance.